Covaxin safe for kids, showed better response than in adults: Bharat Biotech

Covaxin has become the only Covid-19 vaccine in the world to have studied and generated data from trials on kids as young as two years. Results of the trial showed seroconversion at 95-98% in children of all age groups, four weeks after they received their second dose.